论文部分内容阅读
目的探讨 EphA2在膀胱移行细胞癌(BTCC)中的表达及其临床意义。方法采用免疫组织化学 SP 法检测49例 BTCC 及10例癌旁正常组织中 EphA2的蛋白表达,应用实时定量逆转录-聚合酶链反应(real-time RT-PCR)法检测各临床标本相应的 mRNA 表达并通过2~(-△△CT)方法分析相对基因表达的差异。结果相对于癌旁正常组织而言,EphA2在 BTCC 中的蛋白表达显著增强(积分吸光度 IA 均值:正常组8364±3915,癌症组19 122±5696,P<0.01),其 mRNA 表达平均上调约2.57倍;除中分化(G_2)与低分化(G_3)组间 EphA2 mRNA 表达差异无统计学意义(P>0.05)外,EphA2在其余各分级与分期组间的蛋白及核酸表达,差异均具有统计学意义(P<0.05);EphA2的表达与膀胱癌的临床病理特征密切相关。结论 EphA2表达增强可能促进了膀胱癌的恶性晋级,EphA2可作为监测膀胱癌恶性发展的指标和治疗的新靶点。
Objective To investigate the expression of EphA2 in bladder transitional cell carcinoma (BTCC) and its clinical significance. Methods Immunohistochemical SP method was used to detect the expression of EphA2 in 49 cases of BTCC and 10 cases of adjacent normal tissues. Real-time RT-PCR was used to detect the expression of EphA2 mRNA The difference of relative gene expression was analyzed by 2 ~ (- △△ CT) method. Results The expression of EphA2 in BTCC was significantly higher than that in adjacent normal tissues (mean IA value: 8364 ± 3915 in normal group and 19 122 ± 5696 in cancer group, P <0.01), and its mRNA expression was increased by an average of 2.57 Fold; There was no significant difference in the expression of EphA2 mRNA between moderately differentiated (G_2) and poorly differentiated (G_3) groups (P> 0.05) (P <0.05). The expression of EphA2 was closely related to the clinicopathological features of bladder cancer. Conclusion EphA2 expression may promote the malignant progression of bladder cancer. EphA2 may serve as a new target for monitoring the malignant development of bladder cancer and treating it.